• Study on Trastuzumab Deruxtecan and Drug Combination for Patients with High-Risk HER2-Positive Early Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Germany Italy Poland Spain
  • Study on the Safety and Tolerability of KAND567 and Carboplatin for Women with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Denmark Norway Sweden
  • Study of sildenafil to improve walking distance in patients with peripheral arterial disease and intermittent claudication

    Not recruiting

    3 1 1
    Investigated Diseases:
    France
  • Preventing Neovascular Glaucoma in Patients with Large Choroidal Melanoma Using Aflibercept During Proton Therapy

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study of Relatlimab, Nivolumab, and 5-Azacytidine for Acute Myeloid Leukemia in Patients Not Eligible for Intensive Chemotherapy

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Germany
  • Long-term Safety and Efficacy Study of Gene Therapy for Choroideremia and X-Linked Retinitis Pigmentosa Using AAV2-REP1 and AAV8-RPGR in Previously Treated Patients

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany
  • Study on Chlorambucil and Rituximab for Patients with MALT Lymphoma

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    France Italy
  • Study of Leniolisib for Children Aged 4 to 11 with Activated PI3K Delta Syndrome

    Not recruiting

    3 1 1
    Investigated Diseases:
    Investigated Drugs:
    France
  • Study on Long-Term Safety and Efficacy of Cebsulfase Alfa for Children with Late Metachromatic Leukodystrophy Receiving Intrathecal Enzyme Replacement

    Not recruiting

    1 1 1
    Investigated Drugs:
    Czechia Denmark France Germany Italy
  • Study on the Safety of ATreg Cells for Patients with Leukemia After Stem Cell Transplant to Reduce Graft vs Host Disease

    Not recruiting

    2 1 1
    Germany

powered by